Binge Drinking Once a Month Triples Liver Scarring Risk in MASLD Patients

Binge Drinking Linked to Liver Scarring in MASLD Patients

A study published in Clinical Gastroenterology and Hepatology by Keck Medicine of USC found that episodic heavy alcohol consumption—defined as four or more drinks for women or five or more for men at least once monthly—may increase the likelihood of advanced liver fibrosis by threefold in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). The research analyzed data from the National Health and Nutrition Examination Survey (NHANES) 2017–2023, which included over 8,000 adults. The focus on MASLD stems from its widespread prevalence, affecting approximately one in three U.S. adults, and its association with obesity, Type 2 diabetes, hypertension, and hypercholesterolemia. Nearly 16% of MASLD patients were classified as binge drinkers, with over half of participants reporting episodic heavy drinking. Those engaging in large alcohol consumption in a single day at least once monthly were three times more likely to develop advanced liver fibrosis compared to individuals who spread their alcohol intake over time.

“Dr. Brian P. Lee, the study’s principal investigator, noted that binge drinking directly harms the liver by overwhelming it with alcohol, leading to inflammation and scarring. Indirectly, it worsens MASLD risk factors such as obesity and diabetes, which are already linked to severe liver complications.”

MASLD and the Role of Binge Drinking

MASLD, previously termed non-alcoholic fatty liver disease (NAFLD), is now recognized as a distinct condition encompassing both alcohol-related and metabolic factors. It is marked by excessive fat accumulation in the liver, often linked to insulin resistance and metabolic syndrome. The study underscores that MASLD patients face heightened liver damage risks due to the combined effects of obesity and other metabolic disorders, which can more than double the likelihood of liver disease. CDC data indicate that about 17% of U.S. adults engage in binge drinking, a figure consistent with the study’s findings. The 2021 Behavioral Risk Factor Surveillance System (BRFSS) reported a 15.3% binge drinking rate, while 2023 data from young adults aged 18–25 show a 28.7% binge drinking rate, reflecting higher prevalence in younger demographics. The rising prevalence of MASLD, alongside obesity and diabetes, has contributed to a more than doubling of alcohol-related liver disease in the past two decades, driven by pandemic-era drinking surges and worsening metabolic risk factors.

Methodology and Limitations

The study employed an observational design and relied on self-reported alcohol consumption data from NHANES. This method has limitations, as self-reported drinking patterns may not accurately reflect actual behavior. For instance, the study acknowledges potential underreporting or overreporting of alcohol intake, which could affect findings. However, the research found that episodic heavy drinking correlated with significantly higher rates of liver fibrosis, even among individuals with moderate alcohol consumption. Dr. Brian P. Lee, the study’s principal investigator, noted that binge drinking directly harms the liver by overwhelming it with alcohol, leading to inflammation and scarring. Indirectly, it worsens MASLD risk factors such as obesity and diabetes, which are already linked to severe liver complications. The study also observed that younger adults and men were more likely to report episodic heavy drinking, and higher single-day alcohol consumption correlated with greater liver fibrosis. These findings emphasize the importance of considering drinking patterns, rather than total alcohol consumption, when assessing liver risk.

Public Health Implications

The prevalence of episodic heavy drinking in the U.S. highlights the public health significance of this study. CDC data show that approximately 17% of adults engage in binge drinking, with higher rates among young adults (ages 18–25) and certain demographic groups. The National Survey on Drug Use and Health (NSDUH) reports that over 25% of binge drinkers do so weekly, underscoring the widespread nature of this behavior. The study’s findings may apply broadly, as the high prevalence of episodic heavy drinking suggests that even moderate drinkers could face significant liver risks if they engage in binge drinking patterns. This aligns with global trends, where alcohol-related liver disease has surged due to rising obesity rates and metabolic disorders, making MASLD a critical focus for prevention and treatment strategies.

Guidelines for Managing MASLD

The study’s authors stress the importance of addressing episodic heavy drinking as a key factor in liver disease prevention. Public health initiatives should prioritize education on the risks of binge drinking, particularly among individuals with MASLD or metabolic risk factors. The EASL-EASD-EASO 2024 guidelines recommend lifestyle modifications, including weight management, balanced nutrition, and regular physical activity, to mitigate MASLD progression. Dietary interventions such as the Mediterranean diet are specifically highlighted for their role in improving metabolic outcomes. The guidelines emphasize that the Mediterranean diet—rich in olive oil, nuts, fish, and whole grains—can reduce inflammation and improve insulin sensitivity, which are critical for managing MASLD. Additionally, non-invasive diagnostic tools like FibroScan and transient elastography are essential for early detection of liver fibrosis. For individuals with alcohol use disorders, low-alcohol or alcohol-free beverages are recommended to reduce liver damage while maintaining social and recreational drinking habits.